| Miguel Martín, Hospital General Universitario Gregorio Marañón, Madrid, Spain |
| Chair: Ángel Guerrero, Instituto Valenciano de Oncología (IVO), Valencia, Spain |
|
| 16:45 - 17:05 | ESR1 mutations in estrogen receptor positive breast cancer Rachel Schiff, Baylor College of Medicine, Houston, USA |
| 17:05 - 17:25 | Mechanisms of resistance to CDK 4/6 inhibition Rinath Jeselsohn, Dana-Farber/ Harvard Cancer Institute, Boston,USA |
| 17:25 - 17:45 | Relevance of PIK3CA mutations in advanced breast cancer Chi Yan, Vanderbilt University School of Medicine, Nashville, USA |
| 17:45 - 18:15 | Discussion |
| Chair: Luis Costa, Hospital de Santa María, Lisbon, Portugal |
|
| 18:30 - 18:50 | Inmunoconjugates for breast cancer: recent advances Shanu Modi, Memorial Sloan Kettering Cancer Center, New York, USA |
| 18:50 - 19:10 | TKI inhibitiors in HER2-positive breast cancer Sandra Swain, Georgetown University Medical Center, Washington D.C., USA |
| 19:10 - 19:30 | Selective Estrogen Receptor Degraders (SERDs): A New Strategy for Estrogen Receptor Positive Breast Cancer Erika P. Hamilton, Tenneessee Oncology, Nashville, USA |
| 19:30 - 20:00 | Discussion |